ISPOR 2026 News Center

Explore the news and reporting from ISPOR 2026 in the News Center with curated stories on cutting-edge topics from the conference. 

ISPOR 2026

HEOR at the Forefront of Policy, Access, and Value

ISPOR 2026—the Society's annual, international conference—is the largest global conference for health economics and outcomes research (HEOR).

ISPOR 2026 and the Future of HEOR: Navigating an Inflection Point [Rob Abbott/LinkedIn]

From Data to Delivery: How Real-World Evidence Is Transforming Oncology Care [Onco'Zine]

The True Cost of Cancer  [Navlin Daily]

What's The Role Of HEOR For A Clinical Researcher? A Perspective From ISPOR 2026 [Clinical Leader] 

Trump Administration Broadens TrumpRx.gov to Include Generic Medicines [The Evidence Base]

Examining the Feasibility of External Control Arms Across Data Sources in Oncology [The Evidence Base]

ISPOR 2026 Daily Round-Ups: Insights From Day 3  [The Evidence Base]

Understanding Heart Failure Progression: New Insights From Machine Learning Applied to High-Risk Patients [The Evidence Base]

Inside the Third Plenary: Can Global Markets Adapt to the Ripple Effects of US Pricing Policy?  [The Evidence Base]

Strategic Integration of Generative AI in Health Economic Modeling [Navlin Daily]

RWE and Value Assessment in China  [Navlin Daily]

ISPOR 2026 Daily Round Ups: Insights From Day 2 [The Evidence Base]

Inside the Second Plenary: Can Healthcare Systems Balance Cancer Care Costs with Access and Innovation? [The Evidence Base]

Investors Turn Away from MFN to Focus on China [Navlin Daily]

Recent Reforms in HTA, Pricing, & Public Procurement in LATAM [Navlin Daily]

ISPOR 2026 Daily Round-Ups: Insights From Day 1 [The Evidence Base]

Inside the First Plenary: Can US Drug Pricing Reforms Balance Affordability With Incentives for Innovation?  [The Evidence Base]

Is U.S. Pharmaceutical Policy Leading or Following? [Navlin Daily]

Is Value-Based Pricing for CMS Drug Price Negotiation Mission Impossible? [Navlin Daily]

Comparing General-Purpose and Domain-Specific AI in Confounder Identification for HTA Submissions  [The Evidence Base]

EFPIA Report Highlights Widening Disparities in Access to Innovative Medicines Across Europe [The Evidence Base] 

How US Drug Pricing Reforms are Reshaping Biopharma Investment and Innovation  [The Evidence Base] 

Looking Ahead to ISPOR 2026 by Rob Abbott [LinkedIn]

Your Guide to ISPOR 2026  [The Evidence Base]

Living HTA and the Shift Toward Continuous Evidence Assessment: An Interview With Seye Abogunrin and Grammati Sarri  [The Evidence Base]

Perspectives from the Healthcare Economist: Does AI Spell the End of HEOR? [The Evidence Base]

ISPOR 2026 Plenaries and Speakers Announced [ISPOR]

ISPOR 2026 Conference Program Highlights Transformative Role of HEOR in Policy, Access, and Value [The Evidence Base]

Photo Gallery

Additional News From the Conference

ISPOR 2026 Reflections: AI, Access, and the Evolving Role of RWE in Oncology [Flatiron]

AI in HEOR: What ISPOR 2026 Revealed — and What the Field Still Needs to Solve [Komodo Health]

ISPOR 2026: A Brief Recap of Key Themes [blue|matter]

ISPOR 2026 Recap: Understanding Health Between Visits [Evidation]

Perspectives and Directions From ISPOR 2026 [Ana Paula Beck da Silva Etges, PhD, Eng/LinkedIn]

Inside the Real-World Evidence Picture for Hematologic Cancers: TriNetX at ISPOR 2026 [TriNetX]

ImmunityBio (IBRX) Health Economic Analysis Highlights ANKTIVA Value Over TAR-200 [yahoo!finance]

Is Alkermes’ (ALKS) New LYBALVI Real-World Data Quietly Reframing Its Psychiatry Investment Story? [Simply Wall St]

ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation [ImmunityBio]

Egetis to Present Healthcare Resource Drivers and Cost in MCT8 Deficiency at ISPOR 2026 [Market Screener]

Organon Audit Cleared And New Data Put Valuation And Risks In Focus [yahoo!finance]

At ISPOR 2026, RWE Leadership Shifts Toward AI Governance [Paul Mattheneus]

Perspective Mismatch and Static Assumptions: Re-Thinking How Drug Prices Are Specified in US Economic Analyses [iHE]

Truven Launches MarketScan Partner Ecosystem to Expand Real-World Evidence Options [Merative]

Organon to Present New Research on Access and Value at ISPOR 2026  [Business Wire]

[Video]ISPOR 2026 Welcome From RTI [RTI/YouTube]

Jiao to Receive 2026 ISPOR Bernie J. O’Brien New Investigator Award at ISPOR 2026 [USCMann]

Pistoia to Publish Guide to Pharma Firm Social Media Listening [LaboratoryNews]

HEOR News Desk

ISPOR's HEOR News Desk curates the latest HEOR-related news from a variety of news site around the world. 

HEOR News Desk

ISPOR News Webpage

Find the latest ISPOR news and announcements on the Society’s news site.

ISPOR News

Thank You to ISPOR 2026 Media Partners:

A special thank you to the ISPOR 2026 Media Partners—The Evidence Base, Life Science Leader, Clinical Leader. Clinical Tech Leader, Journal of Medical Economics—and to all the media outlets who are reporting on the conference.

Disclaimer:

The reporting on ISPOR 2026 from external news sources reflects the views of the authors/media outlets and is not endorsed by ISPOR.